Neoplasm - Molecular Mechanisms and Genomic Instability

Malignant Neoplasms: DNA Damage and Repair Introduction Cancer is fundamentally a disease of the genome. The development of malignant neoplasms depends critically on accumulating DNA damage that cells fail to repair or properly eliminate. This section explores how DNA damage arises, why some cells accumulate more damage than others, and how this damage drives the progression from normal tissue to cancer. DNA Damage: The Foundation of Cancer Every human cell experiences an enormous amount of DNA damage on a daily basis. In fact, each cell sustains more than 10,000 DNA lesions per day from normal metabolic processes alone—primarily from reactive oxygen species generated during cellular respiration. This might seem alarming, but most of this damage is repaired quickly and effectively by the cell's DNA repair machinery. Cancer arises when damage accumulates because repair systems are either overwhelmed or deficient. This fundamental insight—that DNA damage is the central underlying cause of cancer—shapes our entire understanding of how cancers develop. Sources of DNA Damage DNA damage comes from two main categories: endogenous damage from normal metabolism and exogenous damage from environmental exposures. Environmental (Exogenous) Sources Several well-established environmental factors cause DNA damage that significantly increases cancer risk: Tobacco smoke dramatically increases DNA damage and is the primary cause of lung cancer. Tobacco contains numerous carcinogens that directly bind to and damage DNA. Ultraviolet (UV) radiation from sunlight causes DNA damage in skin cells, specifically creating thymine dimers and other photoproducts that lead to melanoma if left unrepaired. This is why sun exposure and sunburns are risk factors for skin cancer. Helicobacter pylori infection promotes gastric cancer by producing reactive oxygen species that damage DNA in gastric epithelial cells. This bacterium is one of the few infectious agents classified as a carcinogen. High-fat diets raise colonic bile acid levels, which generate reactive oxygen species that damage DNA in colon cells, contributing to colorectal cancer development. These exogenous sources are important because they highlight that cancer risk is not purely genetic—lifestyle and environmental factors play critical roles in DNA damage accumulation. Inherited Mutations in DNA-Repair Genes Some individuals inherit mutated DNA-repair genes that dramatically increase their cancer risk. Currently, mutations in at least 34 different DNA-repair genes have been identified as cancer predisposing factors. These are germline mutations—present in every cell of the body from birth. Inherited mutations in different repair genes confer different levels of risk. Some, like mutations in the TP53 gene (which encodes a critical "guardian of the genome"), confer near-certain lifetime cancer risk. Individuals with Li-Fraumeni syndrome (caused by TP53 mutations) have approximately a 90% lifetime chance of developing cancer and often develop multiple primary cancers. Other inherited mutations in repair genes such as BRCA1, BRCA2, or those affecting mismatch repair (MLH1, MSH2, MSH6, PMS2) significantly elevate cancer risk but don't guarantee cancer development. However, it's important to recognize that inherited mutations account for only about 5-10% of all cancers. The vast majority arise sporadically. Sporadic Cancers and Epigenetic Inactivation Approximately 70% of cancers are sporadic, meaning they lack a hereditary component. In these cases, individuals were born with normally functioning DNA-repair genes, but damage occurs later in life. In sporadic cancers, DNA-repair genes are frequently epigenetically silenced through mechanisms like promoter methylation. Epigenetic silencing is particularly important because: It doesn't involve mutating the DNA sequence of repair genes It effectively turns off gene expression through chemical modifications (typically methylation of cytosine bases in promoters) It can be reversible, though this rarely happens in cancer cells Common examples include epigenetic silencing of MGMT (in glioblastomas), MLH1 and PMS2 (in colorectal cancers). These silencing events occur somatically—in some cells of the body during that person's lifetime—not in germline DNA. The net result is identical to inherited mutations: cells lack functional DNA-repair proteins and cannot efficiently fix DNA damage. Consequences of DNA-Repair Deficiency When DNA-repair genes are deficient (either from inherited mutations or epigenetic silencing), a cascade of consequences follows: Accumulation of DNA damage: Without adequate repair capacity, DNA lesions persist and accumulate in cells. Elevated mutation rates: Unrepaired damage is eventually processed through error-prone repair pathways or translesion synthesis mechanisms that introduce mutations rather than fixing the original damage. Somatic mutations and epimutations: Beyond simple mutations in coding sequences, epigenetic alterations accumulate throughout the genome in repair-deficient cells. Clonal expansion and tumor heterogeneity: As some cells accumulate advantageous mutations (those that promote growth or survival), they outcompete neighboring cells, creating clones of abnormal cells. Further mutations within those clones create sub-populations with different properties, generating the heterogeneity characteristic of tumors. The image above illustrates how endogenous and exogenous DNA damage, combined with DNA-repair deficiency, drives progression to cancer through accumulation of mutations and epigenetic alterations. Genome Instability and Mutation Burden The consequence of deficient repair is genomic instability—the hallmark of cancer. Quantifying Mutations in Tumors The mutation burden in cancers is staggering compared to normal tissues: Average breast or colon cancers contain approximately 60-70 protein-altering mutations in the exome (the protein-coding portion of DNA) Of these, only about 3-4 are driver mutations (mutations that actually promote cancer development); the rest are passenger mutations with no selective advantage Whole-genome sequencing reveals roughly 20,000 total mutations across the entire genome in typical breast and colon cancers Melanomas are even more mutation-heavy, containing approximately 80,000 mutations genome-wide This high mutation burden reflects the chronic inability of repair systems to handle DNA damage. Normal Mutation Rates as a Comparison To put this in perspective, the typical human germline acquires approximately 70 new mutations per generation—a tiny fraction of what accumulates in a single cancer. This dramatic difference illustrates how cancer cells are genomic "mutators" compared to normal cells. Mechanisms Driving Genomic Instability DNA-repair deficiency drives genomic instability through multiple mechanisms working in parallel: Error-prone repair: When damage can't be accurately repaired, cells resort to fallback pathways that introduce mutations while attempting to fix breaks. Translesion synthesis: DNA polymerases that can bypass DNA lesions do so by inserting nucleotides opposite the damage, but these polymerases lack proofreading ability and make frequent mistakes. Epigenetic silencing cascades: Initial epigenetic alterations can trigger further epigenetic changes across the genome, creating widespread dysregulation. Failed checkpoint control: Cells with defective repair often have compromised cell-cycle checkpoints, allowing damaged DNA to be replicated and passed to daughter cells rather than being arrested or eliminated. All of these mechanisms work synergistically to create the characteristic high mutation load of cancer genomes. Epigenetic Alterations in Cancer Beyond mutations, epigenetic changes are critical drivers of cancer: Microsatellite instability frequently accompanies defective DNA mismatch repair. Microsatellites are short, repetitive DNA sequences that are particularly prone to slippage during replication when mismatch repair is defective. Increased microsatellite instability is a clinical marker of mismatch repair deficiency and is observed in many cancers, including head and neck squamous cell carcinomas. MLH1 inactivation through epigenetic silencing (promoter methylation) is particularly common and occurs early in many colorectal cancers, causing widespread mismatch repair deficiency. Widespread epigenetic changes, including DNA methylation patterns and histone modifications, accumulate during progression from precancerous lesions to invasive cancers, exemplified by the progression of Barrett's esophagus to esophageal adenocarcinoma. Field Defects and Field Cancerization One of the most important concepts in understanding cancer progression is field defects (also called field cancerization). What Are Field Defects? Field defects are areas of apparently histologically normal tissue that harbor multiple genetic and epigenetic alterations predisposing to cancer development. These regions can span large areas—from centimeters to entire organs—yet appear microscopically normal. The key insight is that cancer doesn't arise in a single cell in isolation. Rather, an entire field of tissue becomes genetically altered before invasive cancer develops. This explains why patients who develop one cancer in an organ (like the colon or lung) have increased risk of developing additional primary cancers in the same organ. Clonal Expansion Within Field Defects Field defects develop through a stepwise process: Initial alteration: A stem cell acquires a genetic or epigenetic alteration (perhaps in a DNA-repair gene like PMS2) that gives it a slight growth advantage. Clonal expansion: This altered stem cell outcompetes its neighboring stem cells through normal tissue turnover, eventually creating a patch of many cells descended from that single mutant cell—a clone. Sub-clonal diversification: Within this expanded field, additional mutations accumulate. Some cells acquire mutations that make them grow faster or resist apoptosis, causing them to outcompete other cells within the field, creating sub-clones. Progression: This process repeats, with each round of mutation and selection creating more genetically altered sub-clones. Eventually, the accumulation of multiple mutations in a single cell (or a small clone within the field) creates a cell with true neoplastic potential. The image shows field cancerization in colorectal cancer, where multiple areas within the colon harbor independent clones with different genetic alterations, illustrating the multi-focal nature of cancer development. Reconstruction of Tumor Evolution Modern genetic techniques can now reconstruct the chronological sequence of mutations in individual tumors by analyzing clonal architecture. By comparing mutations across different regions of a tumor and identifying which mutations are present in all cells (early, clonal mutations) versus only some cells (later, sub-clonal mutations), researchers can infer the order in which mutations occurred during that tumor's evolution. This has revealed that most colorectal tumors follow a relatively consistent sequence: loss of APC (creating a polyp) → KRAS mutation → loss of TP53 (leading to invasive cancer). However, not all tumors follow this exact sequence, reflecting tumor heterogeneity. Cancer Genome Landscape The complete picture of cancer genetics is captured in what researchers call cancer genome landscapes—comprehensive maps of all somatic mutations, copy-number alterations (gains and losses of chromosome segments), and structural rearrangements across many tumor types. By sequencing thousands of tumors across different cancer types, researchers have identified: Recurrent driver mutations that appear in multiple tumors of the same type Cancer-type-specific mutation patterns reflecting organ-specific exposures and vulnerabilities Complex rearrangements including deletions, duplications, translocations, and inversions Mutational signatures that reveal which DNA-damaging processes (smoking, UV radiation, defective mismatch repair) were active in each tumor This landscape approach has been revolutionary because it reveals that while individual tumors are unique, they follow recurring patterns, allowing prediction of behavior and response to therapy. Summary: From Damage to Cancer The pathway from normal cell to cancer can now be understood as follows: DNA damage occurs constantly from endogenous and exogenous sources Cells normally repair this damage through multiple mechanisms When repair genes are deficient (inherited or epigenetically silenced), damage accumulates Accumulated damage leads to mutation and epigenetic alterations Rare mutations in cancer-related genes (oncogenes and tumor suppressors) drive clonal expansion Selection for cells with growth advantages creates sub-clones within expanding field defects Eventually, a cell acquires enough mutations to become truly neoplastic This cell expands to form a tumor with complex heterogeneity Understanding this process—the central role of DNA damage and repair—is essential for understanding cancer biology and provides targets for prevention (reducing damage exposure) and treatment (exploiting repair deficiencies).